Catherine J. Mackey - 17 Nov 2021 Form 4 Insider Report for Trillium Therapeutics Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 17 Nov 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Nov 2021, 12:26:15 UTC
Prior SEC filing: 02 Jul 2021
Next SEC filing: 16 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ James Parsons, Attorney-in-Fact

Key filing fact

Catherine J. Mackey filed Form 4 for Trillium Therapeutics Inc. on 19 Nov 2021.

Key facts

This page summarizes Catherine J. Mackey's Form 4 filing for Trillium Therapeutics Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Nov 2021, 12:26.

Change

Previous filing in this sequence was filed on 02 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -67,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 67,000
Exercise price: $9.70
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Catherine J. Mackey is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.